New Biomarkers and Immunotherapy Decision

Basit Öğe Kaydı
dc.contributor.authorYigit, Abdurrahman
dc.contributor.authorKuscu, Berkay
dc.contributor.authorKirik, Ali
dc.contributor.authorOzcaglayan, Ruhsen
dc.contributor.authorAfsar, Cigdem Usul
dc.date.accessioned2025-01-27T18:58:58Z
dc.date.available2025-01-27T18:58:58Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAs immune checkpoint blockade and other immune-based therapy approaches lead to broad treatment advances among patients with advanced cancer, an important consideration is how to best select patients whose tumors will respond to these therapies. As a consequence predictive and prognostic markers are needed. There are genomic features, such as tumour mutation burden (TMB), microsatellite instability (MSI), and immune phenotype features, such as programmed death-ligand 1 (PD-L1), CTLA-4 and tumour infiltrating lymphocytes (TILs), to predict response to immunotherapies (ITs). Several studies show the correlation between TMB and predicted neoantigen load across multiple cancer types. Response to immune checkpoint inhibitors is higher in tumours with high TMB. The candidate biomarker that has been studied mostly other than TMB is PD-L1 expression in trials utilizing programmed cell death-1 (PD-1) blockade. PD-L1 and PD-1 expression are dynamic markers that change in relation to local cytokines and other factors, and the thresholds that separate “positive” and “negative” PD-L1 expressions remain under debate. PD-L1 expression is now a routine diagnostic marker for patients with newly diagnosed NSCLC. The potential applicability of PD-L1 in other disease settings is still uncertain. Microsatellite instability is characterised by high rates of alterations to repetitive DNA sequences caused by impaired mismatch repair (MMR); MSI was the biomarker was approved according to tumor's initial location. Combining TMB with specific genomic alterations is crucial. Moreover, new biomarkers are being investigated. © 2022, Bentham Books imprint.
dc.identifier.doi10.2174/9789815040463122010003
dc.identifier.endpage15
dc.identifier.isbn978-981504046-3
dc.identifier.isbn978-981504047-0
dc.identifier.scopus2-s2.0-85210725310
dc.identifier.scopusqualityQ2
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.2174/9789815040463122010003
dc.identifier.urihttps://hdl.handle.net/20.500.12428/13095
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherBentham Science Publishers
dc.relation.ispartofBiomarkers in Medicine
dc.relation.publicationcategoryKitap Bölümü - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250125
dc.subjectCheckpoint inhibitor; Immunotherapy; MSI; PD-L1; PD1; Predictive; Prognostic; TIL; TMB
dc.titleNew Biomarkers and Immunotherapy Decision
dc.typeBook Chapter

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu